Lonjon N, Bauchet L, Duffau H, Fabbro-Peray P, Segnarbieux F, Paquis P, Lonjon M
Département de neurochirurgie, hôpital Gui-de-Chauliac, 80, avenue Augustin-Fliche, 34091 Montpellier cedex 05, France.
Neurochirurgie. 2010 Feb;56(1):36-42. doi: 10.1016/j.neuchi.2009.11.013. Epub 2009 Dec 31.
Glioblastoma, the most common malignant primary brain tumor in adults, is usually rapidly fatal. The current care standards for newly diagnosed glioblastoma consist, when feasible, in surgical resection, radiotherapy, and chemotherapy, as described in the Stupp protocol. Despite optimal treatment, nearly all malignant gliomas recur. If the tumor is symptomatic for mass effect, repeated surgery may be proposed.
We retrospectively analyzed the survival of patients with histologically confirmed primary glioblastoma (WHO grade 4) who were operated in two centers between January 2004 and December 2007. All patients who underwent a second resection for recurrent glioblastoma were included.
During this period, 320 patients were operated in the two centers, with 240 surgical resections and 80 surgical biopsies. In the surgical resection group, 8.3% (20 patients) underwent a second surgical resection for glioblastoma. The mean age was 52 years. At the end of the study, seven patients were alive. The median survival was 24 months and progression-free survival was 7.5 months.
The effect of resection of recurrent glioblastoma on survival has not been extensively studied. No randomized trials have been conducted. Our data were globally identical to other retrospective studies. Selected patients with recurrent glioblastoma may be candidates for repeated surgery when the situation appears favorable based on assessment of the individual patient's factors. Factors such medical history, neurological status, location of the tumor, and progression-free survival have been proven in retrospective studies to give better results.
胶质母细胞瘤是成人中最常见的原发性恶性脑肿瘤,通常迅速致命。如Stupp方案所述,新诊断的胶质母细胞瘤当前的护理标准在可行时包括手术切除、放疗和化疗。尽管进行了最佳治疗,但几乎所有恶性胶质瘤都会复发。如果肿瘤因占位效应出现症状,可能会建议再次手术。
我们回顾性分析了2004年1月至2007年12月在两个中心接受手术的组织学确诊的原发性胶质母细胞瘤(世界卫生组织4级)患者的生存情况。纳入了所有因复发性胶质母细胞瘤接受二次切除的患者。
在此期间,两个中心共有320例患者接受了手术,其中240例进行了手术切除,80例进行了手术活检。在手术切除组中,8.3%(20例患者)因胶质母细胞瘤接受了二次手术切除。平均年龄为52岁。研究结束时,7例患者存活。中位生存期为24个月,无进展生存期为7.5个月。
复发性胶质母细胞瘤切除对生存的影响尚未得到广泛研究。尚未进行随机试验。我们的数据总体上与其他回顾性研究一致。根据对个体患者因素的评估,当情况看起来有利时,部分复发性胶质母细胞瘤患者可能适合再次手术。回顾性研究已证明,病史、神经状态、肿瘤位置和无进展生存期等因素能带来更好的结果。